These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 12065554)

  • 1. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
    Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
    J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curability of advanced Burkitt's lymphoma in children by intensive short-term chemotherapy.
    Gasparini M; Rottoli L; Massimino M; Gianni MC; Ballerini E; Ravagnani F; Pupa S; Fossati-Bellani F
    Eur J Cancer; 1993; 29A(5):692-8. PubMed ID: 8471326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
    Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
    Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
    J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
    Di Nicola M; Carlo-Stella C; Mariotti J; Devizzi L; Massimino M; Cabras A; Magni M; Matteucci P; Guidetti A; Gandola L; Gianni AM
    Br J Haematol; 2004 Sep; 126(6):815-20. PubMed ID: 15352985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
    Reiter A; Schrappe M; Parwaresch R; Henze G; Müller-Weihrich S; Sauter S; Sykora KW; Ludwig WD; Gadner H; Riehm H
    J Clin Oncol; 1995 Feb; 13(2):359-72. PubMed ID: 7844597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
    Adde M; Shad A; Venzon D; Arndt C; Gootenberg J; Neely J; Nieder M; Owen W; Seibel N; Wilson W; Horak ID; Magrath I
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):33-9; discussion 45-8. PubMed ID: 9578060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
    Reiter A; Schrappe M; Ludwig WD; Lampert F; Harbott J; Henze G; Niemeyer CM; Gadner H; Müller-Weihrich S; Ritter J
    Blood; 1992 Nov; 80(10):2471-8. PubMed ID: 1421370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
    Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
    J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol.
    Todeschini G; Tecchio C; Degani D; Meneghini V; Marradi P; Balter R; Zanotti R; Ricetti M; Franchini M; Perona G
    Ann Oncol; 1997; 8 Suppl 1():77-81. PubMed ID: 9187436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
    Ribrag V; Koscielny S; Bosq J; Leguay T; Casasnovas O; Fornecker LM; Recher C; Ghesquieres H; Morschhauser F; Girault S; Le Gouill S; Ojeda-Uribe M; Mariette C; Cornillon J; Cartron G; Verge V; Chassagne-Clément C; Dombret H; Coiffier B; Lamy T; Tilly H; Salles G
    Lancet; 2016 Jun; 387(10036):2402-11. PubMed ID: 27080498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study.
    Bowman WP; Shuster JJ; Cook B; Griffin T; Behm F; Pullen J; Link M; Head D; Carroll A; Berard C; Murphy S
    J Clin Oncol; 1996 Apr; 14(4):1252-61. PubMed ID: 8648381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of B-cell acute lymphoblastic leukaemia in childhood: the BFM experience.
    Reiter A
    Baillieres Clin Haematol; 1994 Jun; 7(2):321-37. PubMed ID: 7803904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcome in adult B-cell acute lymphoblastic leukemia.
    Hoelzer D; Ludwig WD; Thiel E; Gassmann W; Löffler H; Fonatsch C; Rieder H; Heil G; Heinze B; Arnold R; Hossfeld D; Büchner T; Koch P; Freund M; Hiddemann W; Maschmeyer G; Heyll A; Aul C; Faak T; Kuse R; Ittel TH; Gramatzki M; Diedrich H; Kolbe K; Fuhr HG; Fischer K; Schadeck-Gressel C; Weiss A; Strohscheer I; Metzner B; Fabry U; Gökbuget N; Völkers B; Messerer D; Uberla K
    Blood; 1996 Jan; 87(2):495-508. PubMed ID: 8555471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
    Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
    Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.